# Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines

> **NCT00254917** · PHASE4 · COMPLETED · sponsor: **Sanofi** · enrollment: 387 (actual)

## Conditions studied

- Diphtheria
- Tetanus
- Polio
- Pertussis
- Haemophilus Influenzae Type B

## Interventions

- **BIOLOGICAL:** Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine
- **BIOLOGICAL:** Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine

## Key facts

- **NCT ID:** NCT00254917
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-10
- **Primary completion:** 2006-02
- **Final completion:** 2006-02
- **Target enrollment:** 387 (ACTUAL)
- **Last updated:** 2012-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00254917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00254917, "Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT00254917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*